Myelofibrosis: best practices, controversies and 2019 update

References

• Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973–977.
   PubMed Web of Science ®Google Scholar
• Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European union. Eur J Haematol. 2014;92(4):289–297.
   PubMed Web of Science ®Google Scholar
• Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595–600.
   PubMed Web of Science ®Google Scholar
• Masarova L, Bose P, Daver N, et al. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017;59:110–116.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012;87(1):25–33.
   PubMed Web of Science ®Google Scholar
• Geyer HL, Dueck AC, Scherber RM, et al. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm. 2015;9:2015.
   Google Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–4103.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472–1477.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Mora B, Giorgino T, et al. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia. 2017;31(4):970.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861–1869.
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062–1069.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke CM, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1(2):105–111.
   PubMed Web of Science ®Google Scholar
• Sollazzo D, Forte D, Polverelli N, et al. Circulating calreticulin is increased in myelofibrosis: correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly. Mediators Inflamm. 2016;5860657:2016.
   Google Scholar
• Agarwal A, Morrone K, Bartenstein M, et al. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β. Stem Cell Investig. 2016;3:5.
   PubMedGoogle Scholar
• Spivak JL, Neoplasms M. Myeloproliferative neoplasms. N Engl J Med. 2017;376(22):2168–2181.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014;28(7):1568–1570.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Pardanani A, Gangat N, et al. Leukemia risk models in primary myelofibrosis: an international working group study. Leukemia. 2012;26(6):1439–1441.
   PubMed Web of Science ®Google Scholar
• Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220–2228.
   PubMed Web of Science ®Google Scholar
• Grinfeld J, Nangalia J, Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica. 2017;102(1):7–17.
   PubMed Web of Science ®Google Scholar
• Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012;120(20):4168–4171.
   PubMed Web of Science ®Google Scholar
• Rotunno G, Pacilli A, Artusi V, et al. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group. Am J Hematol. 2016;91(7):681–686.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494–1500.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Nicolosi M, Mudireddy M, et al. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia. 2018;32(5):1189.
   PubMed Web of Science ®Google Scholar
• Masarova L, Bose P, Daver NG, et al. Cytogenetic risk stratification in primary versus post-essential thrombocythemia/post-polycythemia vera myelofibrosis. Blood. 2016;128(22):4250.
   Web of Science ®Google Scholar
• Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25(1):82–88.
   PubMed Web of Science ®Google Scholar
• Vaidya R, Caramazza D, Begna KH, et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood. 2011;117(21):5612–5615.
   PubMed Web of Science ®Google Scholar
• Mora B, Giorgino T, Guglielmelli P, et al. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. haematologica. 2018;103(9):e392–e394.
   PubMed Web of Science ®Google Scholar
• Dingli D, Schwager SM, Mesa RA, et al. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer: Interdiscip Int J Am Cancer Soc. 2006;106(9):1985–1989.
   Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88(3):1013–1018.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113(13):2895–2901.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–1708.
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–397.
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310–318.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36(17):1769–1770.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Finke C, et al. Integration of mutations and karyotype towards a Genetics-Based Prognostic Scoring System (GPSS) for primary myelofibrosis. Blood. 2014;124(21):406.
   Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32:1631–1642.
   Web of Science ®Google Scholar
• Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008;111(7):3383–3387.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726–2731.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Alessandro V, Domenica C, et al. A new international multicenter-based model to predict survival in myelofibrosis secondary to polycythemia and thrombocythemia: the Mysec Prognostic Model (MYSEC-PM). Blood. 2014;124(21):1826.
   Web of Science ®Google Scholar
• Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416–1430.
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Ditschkowski M, Bogdanov R, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133(20):2233–2242.
   PubMed Web of Science ®Google Scholar
• Silver RT, Barel AC, Lascu E, et al. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. Cancer. 2017;123(14):2680–2687.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Molecular profiling as a novel tool to predict response to interferon-α2 in MPNs: the proof of concept in early myelofibrosis. Cancer. 2017;123(14):2600–2603.
   PubMed Web of Science ®Google Scholar
• Pizzi M, Silver RT, Barel A, et al. Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol. 2015;28:1315.
   PubMed Web of Science ®Google Scholar
• Cervantes F. How I treat myelofibrosis. Blood. 2014;124(17):2635–2642.
   PubMed Web of Science ®Google Scholar
• Tefferi A. How I treat myelofibrosis. Blood. 2011;117(13):3494–3504.
   PubMed Web of Science ®Google Scholar
• Scherber RM, Geyer H, Dueck AC, et al. Symptom burden as primary driver for therapy in patients with myelofibrosis: an analysis by MPN international quality of life study group. Blood. 2016;128(22):3117.
   Google Scholar
• Silver RT, Vandris K, Goldman JJ. Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011;117(24):6669–6672.
   PubMed Web of Science ®Google Scholar
• Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer. 1998;83(6):1205–1213.
   PubMed Web of Science ®Google Scholar
• Ianotto JC, Chauveau A, Boyer-Perrard F, et al. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French intergroup of myeloproliferative neoplasms (FIM) study. Haematologica. 2018;103(3):438–446.
   PubMed Web of Science ®Google Scholar
• Lundberg LG, Lerner R, Sundelin P, et al. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol. 2000;157(1):15–19.
   PubMed Web of Science ®Google Scholar
• Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol. 1992;3(2):89–96.
   PubMedGoogle Scholar
• Schmitt A, Jouault H, Guichard J, et al. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood. 2000;96(4):1342–1347.
   PubMed Web of Science ®Google Scholar
• Centurione L, Di Baldassarre A, Zingariello M, et al. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Blood. 2004;104(12):3573–3580.
   PubMed Web of Science ®Google Scholar
• Mullally A, Bruedigam C, Poveromo L, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 2013;121(18):3692–3702.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117(18):4706–4715.
   PubMed Web of Science ®Google Scholar
• Ianotto JC, Boyer-Perrard F, Gyan E, et al. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol. 2013;162(6):783–791.
   PubMed Web of Science ®Google Scholar
• Bachleitner-Hofmann T, Gisslinger H. The role of interferon-alpha in the treatment of idiopathic myelofibrosis. Ann Hematol. 1999;78(12):533–538.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013;122(6):893–901.
   PubMed Web of Science ®Google Scholar
• Mikkelsen SU, Kjaer L, Bjørn ME, et al. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Med. 2018;7(8):3571–3581.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395–1398.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):55.
   PubMedGoogle Scholar
• Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian -J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):e317–e324.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Schaap N, Vannucchi AM, et al. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): a reanalysis of the JAKARTA-2 study. J Clin Oncol. 2019;37(15_suppl):7057.
   Web of Science ®Google Scholar
• Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4:652.
   Web of Science ®Google Scholar
• Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73–e81.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844–3850.
   PubMed Web of Science ®Google Scholar
• Eghtedar A, Verstovsek S, Estrov Z, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012;119(20):4614–4618.
   PubMed Web of Science ®Google Scholar
• Badar T, Kantarjian HM, Ravandi F, et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015;39(9):950–956.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Kantarjian H, Kadia T, et al. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(3):171–176.
   PubMed Web of Science ®Google Scholar
• Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010;116(19):3735–3742.
   PubMed Web of Science ®Google Scholar
• Fominykh M, Shuvaev V, Martynkevich I, et al. The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis. Br J Haematol. 2017;178(4):645–646.
   PubMed Web of Science ®Google Scholar
• Assi R, Kantarjian HM, Garcia-Manero G, et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018;93(2):277–285.
   PubMed Web of Science ®Google Scholar
• Mwirigi A, Galli S, Keohane C, et al. Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2014;167(5):714–716.
   PubMed Web of Science ®Google Scholar
• Odenike O. How I treat the blast phase of Philadelphia chromosome–negative myeloproliferative neoplasms. Blood. 2018;132(22):2339–2350.
   PubMed Web of Science ®Google Scholar
• Shanavas M, Popat U, Michaelis LC, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors. Biol Blood Marrow Transplant. 2016;22(3):432–440.
   PubMedGoogle Scholar
• Ballinger TJ, Savani BN, Gupta V, et al. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis. Eur J Haematol. 2015;94(2):115–119.
   PubMed Web of Science ®Google Scholar
• Kröger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29(11):2126–2133.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Jamieson C, Bhatia R, et al. NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018. J Natl Compr Canc Netw. 2017;15(10):1193–1207.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Soraru M, Dominietto A, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant. 2010;45(3):458–463.
   PubMed Web of Science ®Google Scholar
• Gergis U, Kuriakose E, Shore T, et al. Allogeneic transplantation for patients with advanced myelofibrosis: splenomegaly and high serum LDH are adverse risk factors for successful engraftment. Clin Lymphoma Myeloma Leuk. 2016;16(5):297–303.
   PubMed Web of Science ®Google Scholar
• Scott BL, Gooley TA, Sorror ML, et al. The dynamic international prognostic scoring system for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood. 2012;119(11):2657–2664.
   PubMed Web of Science ®Google Scholar
• Robin M, Zine M, Chevret S, et al. The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(6):958–964.
   PubMed Web of Science ®Google Scholar
• Kröger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the chronic leukemia working party of the European group for blood and marrow transplantation. Blood. 2009;114(26):5264–5270.
   PubMed Web of Science ®Google Scholar
• Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367–369.
   PubMed Web of Science ®Google Scholar
• Abelsson J, Merup M, Birgegård G, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant. 2012;47(3):380–386.
   PubMed Web of Science ®Google Scholar
• Murata M, Nishida T, Taniguchi S, et al. Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT. Bone Marrow Transplant. 2014;49(3):355–360.
   PubMed Web of Science ®Google Scholar
• Patriarca F, Bacigalupo A, Sperotto A, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica. 2008;93(10):1514–1522.
   PubMed Web of Science ®Google Scholar
• Robin M, Tabrizi R, Mohty M, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol. 2011;152(3):331–339.
   PubMed Web of Science ®Google Scholar
• Rondelli D, Goldberg JD, Isola L, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014;124(7):1183–1191.
   PubMed Web of Science ®Google Scholar
• Robin M, Giannotti F, Deconinck E, et al. Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. Biol Blood Marrow Transplant. 2014;20(11):1841–1846.
   PubMed Web of Science ®Google Scholar